Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223213 | 1.00 | KMT2A (0.43) | KMT2ASLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12516141 | 1.00 | KMT2A (0.43) | KMT2ASLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL2222676 | 0.99 | KMT2A (0.42) | KMT2ASLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL8406937 | 0.80 | MAP2K1 (0.42) | SLC6A2SLC6A4KCNH2ADRA1DADRA1A | |
| SCHEMBL27880543 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2LMNA | |
| SCHEMBL27880522 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2LMNA | |
| SCHEMBL12516846 | 0.74 | DRD2 (0.60) | KMT2ALMNAMAPTCYP2D6 | |
| SCHEMBL19831677 | 0.74 | DRD2 (0.60) | KMT2ALMNAMAPTCYP2D6 | |
| SCHEMBL13822282 | 0.74 | USP30 (0.47) | — | |
| SCHEMBL12516842 | 0.74 | DRD2 (0.60) | KMT2ALMNAMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| CN-102802627-A | Voltage-gated sodium channel blockers | GLAXO GROUP LTD | 2012-11-28 | — | — | CN | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | KMT2A 2744/4885SLC6A2 241/4885SLC6A4 295/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | KMT2A 3151/4885SLC6A2 242/4885SLC6A4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.